Akademik Veri Yönetim Sistemi
Klinik Gelisim, cilt.9, sa.1, ss.4019-4025, 1996 (Scopus)
To investigate the effects of metformin on insulin sensitivity, blood pressure, carbohydrate and lipid metabolism in hypertensive patients with impaired glucose tolerance, 12 subjects (8 females and 4 males) were enrolled in a single-blind study encompassing 8 weeks of placebo and 8 weeks of metformin treatment. The findings were compared with those of 15 healthy subjects matched for sex and age. Insulin sensitivity was assessed by an intravenous insulin tolerance test (ITT). Fasting plasma levels of insulin, total cholesterol, triglyceride, low density lipoprotein cholesterol (LDL-C), uric acid and the areas under the curve (AUC) for plasma glucose and insulin during oral glucose tolerance test (OGTT) were significantly higher whereas insulin sensitivity and high density lipoprotein cholesterol (HDL-C) were lower in the hypertensive patients with impaired glucose tolerance than those in the normal subjects. There were no significant changes in insulin sensitivity, blood pressure and the other parameters following the placebo treatment. After the metformin treatment insulin sensitivity [the plasma glucose disappearance rate (K(itt)] increased significantly (K(itt): 1.58 (0.7-3.2) %/min [at baseline] versus 2.3 (1.1-3.6) %/min [after metformin], p<0.001) whereas both systolic and diastolic blood pressure decreased significantly (p<0.05). Fasting plasma levels of insulin, total cholesterol, triglyceride, LDL-C, uric acid and the AUC for plasma glucose and insulin decreased significantly, whereas HDL-C increased by the metformin treatment. These results show that metformin treatment in hypertensive subjects with impaired glucose tolerance produces a more favorable cardiovascular risk profile by reducing insulin resistance and associated metabolic abnormalities and blood pressure.